Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 14
1988 6
1989 6
1990 10
1991 9
1992 13
1993 8
1994 20
1995 32
1996 34
1997 33
1998 50
1999 33
2000 22
2001 30
2002 20
2003 33
2004 27
2005 31
2006 33
2007 22
2008 23
2009 18
2010 19
2011 24
2012 18
2013 14
2014 9
2015 13
2016 17
2017 18
2018 19
2019 18
2020 27
2021 29
2022 20
2023 14
2024 21
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

750 results

Results by year

Filters applied: . Clear all
Page 1
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Cornely OA, et al. N Engl J Med. 2007 Jan 25;356(4):348-59. doi: 10.1056/NEJMoa061094. N Engl J Med. 2007. PMID: 17251531 Free article. Clinical Trial.
We compared the incidence of proven or probable invasive fungal infections during treatment (the primary end point) between the posaconazole and fluconazole or itraconazole groups; death from any cause and time to death were secondary end points. RESULTS: A total of 304 pa …
We compared the incidence of proven or probable invasive fungal infections during treatment (the primary end point) between the posaconazole …
Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin - A prospective, randomized comparative study.
Bhatia A, Kanish B, Badyal DK, Kate P, Choudhary S. Bhatia A, et al. Indian J Pharmacol. 2019 Mar-Apr;51(2):116-119. doi: 10.4103/ijp.IJP_578_17. Indian J Pharmacol. 2019. PMID: 31142947 Free PMC article. Clinical Trial.
Therefore, this study was designed to compare the efficacy of terbinafine and itraconazole in increased dosages and duration in the treatment of tinea corporis and tinea cruris. ...CONCLUSIONS: Itraconazole and terbinafine seem to be equally effective and safe in th …
Therefore, this study was designed to compare the efficacy of terbinafine and itraconazole in increased dosages and duration in the t …
Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial.
Liesenborghs L, Spriet I, Jochmans D, Belmans A, Gyselinck I, Teuwen LA, Ter Horst S, Dreesen E, Geukens T, Engelen MM, Landeloos E, Geldhof V, Ceunen H, Debaveye B, Vandenberk B, Van der Linden L, Jacobs S, Langendries L, Boudewijns R, Do TND, Chiu W, Wang X, Zhang X, Weynand B, Vanassche T, Devos T, Meyfroidt G, Janssens W, Vos R, Vermeersch P, Wauters J, Verbeke G, De Munter P, Kaptein SJF, Rocha-Pereira J, Delang L, Van Wijngaerden E, Neyts J, Verhamme P. Liesenborghs L, et al. EBioMedicine. 2021 Apr;66:103288. doi: 10.1016/j.ebiom.2021.103288. Epub 2021 Mar 19. EBioMedicine. 2021. PMID: 33752127 Free PMC article. Clinical Trial.
BACKGROUND: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical and clinical studies are required to investigate if itraconazole is effective for the treatment and/or prevention of COVID-19. ...In …
BACKGROUND: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical …
Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial.
Shenoy MM, De A, Shah B, Das A, Saraswat A, Lahiri K, Yadav S, Sarda A, Chakraborty D, J D, Kamat S, Doshi Y, Gonsalves N, Choudhary A, Dhoot D, Mahadkar N, Bhushan S, Gadkari R, Barkate H. Shenoy MM, et al. Drug Des Devel Ther. 2023 Sep 21;17:2899-2908. doi: 10.2147/DDDT.S421583. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 37766823 Free PMC article. Clinical Trial.
INTRODUCTION: Itraconazole follows non-linear pharmacokinetics and hence is recommended once daily, but in real-world practice, is commonly prescribed as twice daily. Hence, this study aimed to evaluate the efficacy and safety of super-bioavailable-itraconazole-130 …
INTRODUCTION: Itraconazole follows non-linear pharmacokinetics and hence is recommended once daily, but in real-world practice, is co …
Itraconazole Improved Bronchial Wall Thickness in Severe Persistent Asthma: A Double-blind Placebo-controlled Randomized Clinical Trial.
Aligolighasemabadi F, Mirsadraee M, Sadeghdoust M, Ghaffari S, Sarafraz Yazdi M, Naghibi S, Hashemi Attar A. Aligolighasemabadi F, et al. Iran J Allergy Asthma Immunol. 2023 Feb 20;22(1):1-11. doi: 10.18502/ijaai.v22i1.12000. Iran J Allergy Asthma Immunol. 2023. PMID: 37002624 Free article. Clinical Trial.
Wall thickness percentage reduced significantly from 46% to 43.7% from pre- to post-treatment in the itraconazole-treated subjects. Similarly, lumen area and radius increased significantly in both the prednisolone and itraconazole groups. Itraconazole led to …
Wall thickness percentage reduced significantly from 46% to 43.7% from pre- to post-treatment in the itraconazole-treated subjects. S …
Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature.
Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A. Agarwal R, et al. Mycoses. 2013 Sep;56(5):559-70. doi: 10.1111/myc.12075. Epub 2013 Mar 18. Mycoses. 2013. PMID: 23496375 Review.
A total of 31 patients (mean age, 37 years) were randomised to itraconazole (n = 17) or the control (n = 14) group. The number of patients showing overall response was significantly higher in the itraconazole group (76.5%) vs. the control (35.7%) group (P = 0.02). . …
A total of 31 patients (mean age, 37 years) were randomised to itraconazole (n = 17) or the control (n = 14) group. The number of pat …
Cold atmospheric plasma therapy for Malassezia folliculitis: Laboratory investigations and a randomized clinical trial.
Wang N, Yan T, Mei X, Liu J, Lei Y, Yang C. Wang N, et al. Skin Res Technol. 2024 Jul;30(7):e13850. doi: 10.1111/srt.13850. Skin Res Technol. 2024. PMID: 38979986 Free PMC article. Clinical Trial.
At week 2, success was achieved by 40.0% of subjects in the CAP group versus 58.3% in the itraconazole group (p = 0.199). The negative direct microscopy rates of follicular samples were 56.0% in the CAP group versus 66.7% in the itraconazole group (p = 0.444). ...Th …
At week 2, success was achieved by 40.0% of subjects in the CAP group versus 58.3% in the itraconazole group (p = 0.199). The negativ …
A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis.
Le T, Kinh NV, Cuc NTK, Tung NLN, Lam NT, Thuy PTT, Cuong DD, Phuc PTH, Vinh VH, Hanh DTH, Tam VV, Thanh NT, Thuy TP, Hang NT, Long HB, Nhan HT, Wertheim HFL, Merson L, Shikuma C, Day JN, Chau NVV, Farrar J, Thwaites G, Wolbers M; IVAP Investigators. Le T, et al. N Engl J Med. 2017 Jun 15;376(24):2329-2340. doi: 10.1056/NEJMoa1613306. N Engl J Med. 2017. PMID: 28614691 Free article. Clinical Trial.
Treatment with amphotericin was associated with significantly faster clinical resolution and fungal clearance and significantly lower rates of relapse and IRIS than itraconazole. The patients who received amphotericin had significantly higher rates of infusion-related reac …
Treatment with amphotericin was associated with significantly faster clinical resolution and fungal clearance and significantly lower rates …
Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial.
Deng K, Zou Y, Zou C, Wang H, Xiang Y, Yang X, Yang S, Cui C, Yang G, Huang J. Deng K, et al. Cancer Med. 2023 Jan;12(2):1431-1440. doi: 10.1002/cam4.5028. Epub 2022 Jul 16. Cancer Med. 2023. PMID: 35841331 Free PMC article. Clinical Trial.
METHODS: We conducted a single-center, open-label pharmacokinetic study of itraconazole on SHR2554 in 18 healthy Chinese subjects. Subjects were orally administrated SHR2554 50 mg on Day 1, itraconazole 200 mg Quaque Die (QD) from Days 4 to 7, SHR2554 50 mg co-admin …
METHODS: We conducted a single-center, open-label pharmacokinetic study of itraconazole on SHR2554 in 18 healthy Chinese subjects. Su …
Efficacy and safety of miconazole muco-adhesive tablet versus itraconazole in oropharyngeal candidiasis: A randomized, multi-centered, double-blind, phase 3 trial.
Wang Y, Zhou H, Wang W, Duan N, Luo Z, Chai H, Jiang L, Chen Q, Liu J, Hua H, Yan Z, Fan Y, Xu J, Guan X, Wang H, Lu H, Lun W, Fei W, Zhang T, Zhao J, Jia C, Kong H, Shen X, Liu Q, Wang W, Tang G. Wang Y, et al. Med Mycol. 2022 Nov 3;60(11):myac076. doi: 10.1093/mmy/myac076. Med Mycol. 2022. PMID: 36149321 Clinical Trial.
Herein, we evaluate the efficacy and safety of miconazole buccal tablets (MBT) and itraconazole capsules in the localized treatment of patients with OPC. In this multi-centered, double-blinded, phase III trial (CTR20130414), both males and non-pregnant females (18 years) w …
Herein, we evaluate the efficacy and safety of miconazole buccal tablets (MBT) and itraconazole capsules in the localized treatment o …
750 results